Advertisement

Topics

U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer

12:45 EST 12 Jan 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
LYNPARZA is the Only PARP Inhibitor Approved for Use Beyond Ovarian Cancer LYNPARZA Reduced Risk of Disease Progression or Death by 42 Percent Compared to Standard of Care Chemotherapy AstraZeneca and Merck (...

Other Sources for this Article

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-442-5695
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

NEXT ARTICLE

More From BioPortfolio on "U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...